VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
The expansion of the patent portfolio is significant for VERAXA as it seeks to establish a competitive moat in the rapidly evolving field of cancer immunotherapy. By securing intellectual property rights on key technologies such as the BiTAC platform, the company aims to protect its investments in research and development and create barriers to entry for potential competitors. The patents cover innovations that could lead to more precise and effective cancer treatments, potentially improving patient outcomes and reducing side effects compared to traditional therapies.
VERAXA's focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, positions it at the forefront of oncology drug development. The company's technologies are based on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution. With a portfolio of more than 50 patents across multiple countries, VERAXA is building a strong foundation for its pipeline of therapies. The company's forward-looking statements indicate that it is actively advancing its programs toward clinical development, with the expectation that its core technologies will be protected for decades to come.
For more details on the announcement, visit the full press release at https://ibn.fm/BqhFS. Further information about VERAXA and its latest news can be found in the company's newsroom at https://ibn.fm/VRXA.
